|
?:reviewBody
|
-
When Susan Goodman Komen died of breast cancer at the age of 33 in 1980, her younger sister, Nancy Goodman Brinker promised she would do whatever she could to help end that disease. Brinker fulfilled that promise by founding The Susan G. Komen Breast Cancer Foundation (later known as Susan G. Komen for the Cure, then just Susan G. Komen) in 1982, a group that has since become the largest and most well known breast cancer organization in the United States: In 2012, Komen founder and CEO Nancy Brinker became the focus of controversy when she announced Komen would be pulling the grants the organization had been providing to Planned Parenthood for breast cancer screenings, then quickly reversed that decision. Several months later Brinker announced she would be stepping down as Komen's CEO, but the following year she was again the focus of controversy when news outlets reported that not only did she still hold her CEO position, but she had received a hefty raise to boot that brought her annual compensation up to $684,000 per year: Charity Navigator's last compensation figure for Nancy Brinker was $560,896 per year, which at the time put her below Komen president Elizabeth Thompson's reported annual compensation of $606,461. In June 2013, Komen finally announced that Brinker would be stepping down as president and CEO of that organization and named Judith A. Salerno, M.D. as her successor. In June 2015, Brinker reportedly resigned from her paid position to assume an unpaid role role as a top volunteer with Komen. Dr. Salerno's most recently reported compensation (in August 2017) was $479,858, while Nancy Brinker was still listed as a founder receiving a salary of $397,093. In September 2017, Paula Schneider took over as president and CEO of Komen, with compensation of $137,155 reported as of the end of the fiscal year in March 2018. The reference to Komen's applying only 20% of donated money to breast cancer research likely comes from a pie chart displayed in the Use of Funds section of Wikipedia's article about Susan G. Komen for the Cure, which showed Komen's 2009-2010 Expenses: While it may have been true that breast cancer research comprised only a 21% share of Komen's program expenses (Charity Navigator puts the figure at 28.8% as of March 2018), citing that figure as a criticism of the organization reflects a common misbelief that groups dedicated to addressing particular diseases (e.g., the Muscular Dystrophy Association, the ALS Association) exist solely or primarily to fund and direct research into curing and/or preventing those diseases. This perception is inaccurate: Komen and other groups like it have goals that include delivering a wide array of services to the communities they support beyond the funding of research, such as funding educational awareness and outreach programs, providing screening and diagnostic procedures, and arranging medical treatment and home care for persons currently living with those diseases. A more relevant metric for assessing a charity's overall financial effectiveness is the percentage of the organization's budget that is actually spent on all the programs and services the charity delivers, and in this area the Charity Navigator charity evaluation site gives Komen an 80.3 rating (as well as a 96.0 rating for Accountability & Transparency). Charity Navigator does rank many other breast cancer charities higher than Susan G. Komen for the Cure, however. Regarding the seemingly excessively high level of CEO salaries at some charities, Charity Navigator advises that:
(en)
|
![[This page as RDF]](http://data.gesis.org/claimskg/static/rdf-icon.gif){kind=icon}